Quick Take
Lixte Biotechnology Holdings (LIXT) has filed to raise $10 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is developing a pipeline of treatments for various types of cancers and vascular and metabolic diseases.
LIXT is outsourcing its clinical trials for its primary compound and likely intends to partner/license the drug upon successful completion of Phase 2 trials, an unusual approach.
I'll provide a final opinion when we learn more about the IPO from management.
Company & Technology
East Setauket, New York-based Lixte